Differential effects of cannabis constituents on schizophrenia-related psychosis: a rationale for incorporating cannabidiol into a schizophrenia therapeutic regimen
Kennadi Johnson, A. Weldon, Melissa A. Burmeister
Frontiers in Psychiatry April 23, 2024 DOI: 10.3389/fpsyt.2024.1386263 (opens in new tab)
Study at a glance
AI-extracted from the abstractAbstract
Schizophrenia is a serious mental health disorder that confers one of the highest mortality rates of all psychiatric illnesses. Although the disorder’s psychotic symptoms are treatable with conventional antipsychotics, they remain incurable. Moreover, medication adherence is poor, and individuals with schizophrenia choose to self-medicate with illicit substances, including cannabis. It is well-established that the delta-9-tetrahydrocannabinol (delta-9-THC) component of cannabis elicits psychotomimetic effects at high doses; worsens schizophrenia-related psychosis; commonly develops into cannabis use disorder in individuals with schizophrenia; and increases the risk of earlier-onset schizophrenia symptoms in those harboring genetic susceptibility. However, individuals with schizophrenia commonly use cannabis and cannabis derivatives such as cannabidiol (CBD). These products seem to alleviate psychotic symptoms and relieve adverse side effects of antipsychotic medications. Therefore, one notion that has gained traction is the potential utility of cannabis-derived cannabidiol (CBD) as adjunct treatment to reduce schizophrenia-associated psychosis and other symptoms. Currently, preclinical and clinical data remain inconclusive. The present review distinguishes the mechanisms underlying schizophrenia-associated vs. cannabis-induced psychosis; reviews the evidence for delta-9-THC-mediated exacerbation vs. CBD-mediated amelioration of schizophrenia-associated psychosis; and describes potential approaches for incorporating CBD into schizophrenia therapeutic regimen in a safe and efficacious manner.
Comparable studies
Other narrative reviews on CBD, most cited first.
Citations in the library
Cites 12
- Gone to Pot – A Review of the Association between Cannabis and Psychosis Frontiers in Psychiatry May 22, 2014
- The Association Between Cannabis Use and Schizophrenia: Causative or Curative? A Systematic Review Cureus July 21, 2020
- Unraveling the Intoxicating and Therapeutic Effects of Cannabis Ingredients on Psychosis and Cognition Frontiers in Psychology May 14, 2020
- Cannabis and Psychosis Through the Lens of DSM-5 International Journal of Environmental Research and Public Health October 28, 2019
- The acute effects of cannabis with and without cannabidiol in adults and adolescents: A randomised, double‐blind, placebo‐controlled, crossover experiment Addiction February 8, 2023
and 7 more in the library